Understanding why hookworms resist treatment with pyrantel
Official title: Dissecting the mechanism of pyrantel resistance in hookworm
Funded at George Washington University · NIH-10764937 · Data updated 2026-11-12
This study is looking into why some hookworms are becoming resistant to the medicine pyrantel, which is often used to treat infections, so we can create better tests and treatments for people, especially kids and pregnant women, who need help fighting these infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | January 17, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,875 |
| NIH project number | 5R21AI166279-02 |
| Project ID | NIH-10764937 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in developing countries who are at risk of hookworm infections, particularly children, pregnant women, and the elderly.
✕Less likely to help
Patients who are not infected with hookworms or who live in regions where hookworm is not prevalent may not benefit from this research.
What this research studies
This research investigates the mechanisms behind hookworm resistance to the drug pyrantel, which is commonly used to treat infections. By analyzing genetic mutations in hookworms, the study aims to develop molecular tests that can detect emerging drug resistance. This approach will help improve treatment strategies during mass drug administration programs, particularly in vulnerable populations such as children and pregnant women. The research focuses on understanding how resistance develops to ensure effective control of hookworm infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hookworm infections, reducing anemia and improving health outcomes in affected populations.
How similar studies have gone: Other research has shown success in understanding drug resistance in parasitic infections, indicating that this approach could yield valuable insights.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Hawdon, John M — George Washington University
- Study coordinator: Hawdon, John M
Related research
Other NIH-funded projects on the same topics.
-
HLA-F and KIR3DS1: unlocking NK cell help to control HIV
A short, patient-friendly look at how a specific immune interaction might help the body control HIV and reduce long-term health problems.
-
Emerging therapies for rare maternal mitochondrial diseases with shared causes
A basket clinical trial will test new drug candidates for two ultra-rare mitochondrial diseases (MELAS and LHON-Plus) that share the same underlying energy-making problem in people who could be affected.
-
Anti-cancer vaccine for liver fluke infection and bile duct cancer
A vaccine approach aims to stop liver fluke interactions with the human bile ducts to prevent bile duct cancer in regions where the parasite is common.
-
Anti-cancer vaccine targeting the host-parasite interface during liver fluke infection
A vaccine approach aims to block how a liver fluke parasite communicates with the human liver to prevent bile duct cancer in people in Southeast Asia.
-
Understanding why youth develop type 2 diabetes and how to prevent it
A nationwide study aims to unravel why some teens with obesity develop type 2 diabetes while others don’t, and to identify factors that could help prevent it.
-
Ultrasensitive antibody-detection method to screen HIV-bNAbs
A new, ultra-sensitive test will help identify which broadly neutralizing antibodies can best block HIV-1 in people, by quickly checking how well these antibodies interact with the virus in patient-derived samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.